We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 140.00
Bid: 135.00
Ask: 145.00
Change: 12.50 (9.80%)
Spread: 10.00 (7.407%)
Open: 127.50
High: 140.00
Low: 127.50
Prev. Close: 127.50
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Faron appoints Sensei Biotherapeutics's Marie-Louise Fjallskog as CMO

Tue, 04th Jan 2022 15:54

(Alliance News) - Faron Pharmaceuticals Oy announced the appointment of Marie-Louise Fjallskog as new chief medical officer on Tuesday.

Fjallskog will join the Finland-based clinical-stage biopharmaceutical company, bringing 30 years of experience in clinical oncology, translational research and drug development.

She was previously chief medical officer at Nasdaq-listed Sensei Biotherapeutics Inc, where she played a key role in the company's USD150 million IPO in the first quarter of 2021.

Faron's chief executive officer, Markku Jalkanen, said: "I am delighted to welcome Marie-Louise to Faron as our Chief Medical Officer during what is a critical time for the Company as we accelerate the execution of our ambitious clinical development programs, including our lead oncology asset bexmarilimab."

The pharmaceutical company's share price rose by 8.4% to 290.00 pence on Tuesday afternoon in London.

By Elizabeth Winter; elizabethwinter@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
11 May 2020 16:48

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Faron Pharma Gets EUR800,000 Grant From Finnish Cancer Consortium

Read more
11 May 2020 16:03

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
5 May 2020 12:05

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Faron Pharmaceuticals Picks Manufacturing Partner For Clevegen Therapy

Read more
5 May 2020 09:20

Faron Pharmaceuticals inks manufacturing deal with AGC Biologics

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has selected contract development and manufacturing organisation AGC Biologics as the commercial-scale manufacturer of 'Clevegen', it announced on Tuesday.

Read more
27 Apr 2020 13:52

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

UK EXECUTIVE CHANGE SUMMARY: Corero Hires Former CML Finance Director

Read more
27 Apr 2020 13:51

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

UK TRADING UPDATE SUMMARY: Novacyt Called Upon To Ramp Up UK Testing

Read more
22 Apr 2020 18:42

Faron Raises EUR14 Million In Oversubscribed Share Placing

Faron Raises EUR14 Million In Oversubscribed Share Placing

Read more
21 Apr 2020 18:21

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Faron Pharmaceuticals Plans Private Placing To Raise EUR10 Million

Read more
1 Apr 2020 17:56

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

UK TRADING UPDATE SUMMARY: Watkin Jones Cancels Payout, Halts Work

Read more
20 Mar 2020 11:25

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Research And Development Expense Drop Cuts Faron Pharmaceuticals Loss

Read more
20 Mar 2020 10:49

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

UK WINNERS & LOSERS SUMMARY: Future Surges As It Sees Results In Line

Read more
13 Mar 2020 16:04

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
9 Mar 2020 14:07

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Faron Pharmaceuticals Gets Green Light For New Traumakine Trial

Read more
9 Mar 2020 10:26

Faron gets FDA tick from proposed design of next 'Traumakine' study

(Sharecast News) - Faron Pharmaceuticals announced on Monday that the US Food and Drug Administration (FDA) has accepted its proposed protocol design for the next 'Traumakine' study in acute respiratory distress syndrome (ARDS) patients, following its protocol submission in February.

Read more
5 Mar 2020 14:28

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Faron Pharmaceuticals "Encouraged" After Latest Matins Trial Findings

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.